The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.
 
Patrick Schoffski
Consulting or Advisory Role - Adaptimmune (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Intellisphere (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Plexxikon (Inst); SERVIER (Inst); Transgene (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Olivier Mir
Stock and Other Ownership Interests - Transgene
Honoraria - Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche; SERVIER; Vifor Pharma
Speakers' Bureau - Lilly; Roche
Travel, Accommodations, Expenses - Pfizer; PharmaMar; Roche
 
Bernd Kasper
Honoraria - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Clinigen Group; Eisai; Lilly
Research Funding - PharmaMar (Inst)
 
Zsuzsanna Papai
No Relationships to Disclose
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - Bayer; GlaxoSmithKline; Lilly; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Other Relationship - Innate Pharma
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
 
Charlotte Benson
No Relationships to Disclose
 
Katerina Kopeckova
Honoraria - Pfizer
Travel, Accommodations, Expenses - Bayer; Roche; Sanofi
 
Nasim Ali
No Relationships to Disclose
 
Palma Dileo
No Relationships to Disclose
 
Axel Le Cesne
Honoraria - Amgen; Lilly; PharmaMar
 
Franka Menge
No Relationships to Disclose
 
Sophie Cousin
No Relationships to Disclose
 
Celine Charon-Barra
No Relationships to Disclose
 
Agnieszka Wozniak
No Relationships to Disclose
 
Sandrine Marreaud
No Relationships to Disclose
 
Saskia Litiere
No Relationships to Disclose
 
Axelle Nzokirantevye
No Relationships to Disclose
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
Other Relationship - Daiichi Sankyo